Opus Genetics Enters Agreement for $25 Million Private Placement

Published on February 18, 2026
RESEARCH TRIANGLE PARK, N.C.—Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced that it has entered into a securities purchase agreement (SPA) for a private placement of 7,374,632 shares of its Series B non-voting convertible preferred stock at a price of $3.39 per share.
Continue reading on website
Other news

AAO’s Updated PPP for POAG Emphasizes Individualized Monitoring

February 18, 2026
Winners in the new AAO guidance include corneal hysteresis, sustained-release therapy, SLT and minimally invasive surgeries, all of which are given greater prominence in glaucoma management. Notable refinements also affect the use of OCT and perimetry. Click image to enlarge. Last week, the American Academy of Ophthalmology (AAO) released four new Preferred Practice Pattern

BostonSight Reveals Five-Year Strategic Road Map to Advance Lens Technology

February 18, 2026
NEEDHAM, Mass.—BostonSight announced it has developed a transformative five-year strategic roadmap aimed at redefining ocular surface treatment through groundbreaking advancements in clinical research, education, and specialty lens technology. BostonSight stated that it has designated key leadership roles to head initiatives that accelerate innovation and collaboration, with the goal of positively